<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656265</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 197-008</org_study_id>
    <nct_id>NCT01656265</nct_id>
  </id_info>
  <brief_title>Study of ARQ 197 in Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Phase I Study of ARQ 197 in Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of ARQ 197 in
      hepatocellular carcinoma (HCC) patients treated with daily oral ARQ 197, to determine the
      recommended dose of ARQ 197 in advanced HCC patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerability</measure>
    <time_frame>DLT observation period will be the first 28 days after the start of ARQ 197 treatment.</time_frame>
    <description>Adverse Event collection and assessment will be done for all treated subjects to assess the safety, tolerability. The grading for the severity of the adverse events will be determined according to CTCAE ver 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profiles of Pharmacokinetics</measure>
    <time_frame>Plasma sample correction at pre-dose 1, 2, 4, 6, 10, 12 and 24 hours on day 1; at pre-dose, 1, 2, 4, 6, 10, 12 hours on day 15; and at pre-dose on day 29.</time_frame>
    <description>maximum concentration (Cmax), area under the curve (AUC), half-life (t1/2), apparent clearance (Cl/F), and apparent volume of distribution in the terminal elimination phase (Vz/F).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor effects according to RECIST 1.1.</measure>
    <time_frame>Every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>ARQ 197</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 197</intervention_name>
    <description>Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.</description>
    <arm_group_label>ARQ 197</arm_group_label>
    <other_name>Tivantinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HCC patients who are resistant to, intolerable to, or rejecting a systemic
             sorafenib therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Child-Pugh classification A at the time of registration

          -  Adequate bone marrow, liver, and renal functions within 14 days prior to registration

        Exclusion Criteria:

          -  Prior therapy with a c-Met inhibitor (including ARQ 197)

          -  Any systemic anti-tumor treatment or investigational agent within 2 weeks prior to
             registration. If the treatment/agent was antibody, within 4 weeks

          -  Local treatment for malignancy within 4 weeks prior to registration

          -  Major surgical procedure within 4 weeks prior to registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kashiwa-city</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

